DNA-Launched iDNA Vaccines

Medigen’s patented DNA-launched vaccine technology (iDNA vaccines) combines genetic stability of DNA with the exceptional efficacy of live attenuated vaccines. This novel platform uses DNA to prepare safe, live attenuated vaccines. 

This approach can be used either to (1) prepare vaccine from iDNA in cell culture (classic vaccine), or (2) to vaccinate patient directly with novel iDNA vaccine. The advantages of Medigen’s iDNA technology include natural immunity and a higher level of safety, the latter resulting from the genetic stability of iDNA. In addition, cold chain may not be needed, as iDNA can be formulated for ambient temperature. 

This technology has been applied at Medigen for vaccine development against emerging RNA viruses with global public health impact including alphaviruses and flaviviruses.